A biomarker for glaucoma diagnosis and its application

By detecting the expression level of ALDH1A1 in aquaculture, the accuracy of early diagnosis of glaucoma is solved, high sensitivity and specific diagnosis of glaucoma are achieved, and potential strategies for treatment are provided to reduce retinal ganglion cells by inhibiting the expression of ALDH1A1 apoptosis delays disease progression.

CN118425510BActive Publication Date: 2024-11-19SHANGHAI FIRST PEOPLES HOSPITAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410618641.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-17
Publication Date
2024-11-19
Estimated Expiration
2044-05-17

AI Technical Summary

Technical Problem

The existing technology is difficult to accurately diagnose in the early stages of glaucoma, and the existing diagnostic methods cannot detect early damage to retinal ganglion cells, resulting in the disease progression to the middle and late stages. The current fecal calprotectin detection method has misdiagnosis or missed diagnosis. risk.

Method used

ALDH1A1 is used as a biomarker of glaucoma, and diagnosed by detecting the expression level of ALDH1A1 in aquaculture. The expression of ALDH1A1 is significantly improved in glaucoma patients, and it has shown an effect of promoting retinal ganglion cell apoptosis in in vitro experiments, providing for Reagents and medications for diagnosis, prognosis evaluation and treatment.

Benefits of technology

Achieve high sensitivity and specificity for early diagnosis of glaucoma, can accurately diagnose in angle-closing and open-angle glaucoma, and has potential applications for prognostic evaluation and treatment, reducing retinal ganglion by inhibiting or regulating ALDH1A1 expression Apoptosis of cells delays disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118425510B_ABST
    Figure CN118425510B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of biomedical technology, and in particular to a biomarker for glaucoma diagnosis and its application. The present invention discloses using ALDH1A1 in human aqueous humor as a biomarker for glaucoma diagnosis. ALDH1A1 has high universality, sensitivity and specificity in the diagnosis of different types of glaucoma patients. In addition, ALDH1A1 can promote ganglion cell apoptosis in vitro, indicating that ALDH1A1 may participate in the occurrence of glaucoma and related diseases by promoting ganglion cell apoptosis, and is expected to become a therapeutic target.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a biomarker for glaucoma diagnosis and application thereof. Background Art

[0002] Glaucoma is a group of diseases that threaten and damage the optic nerve and its visual pathways, leading to visual dysfunction. It is the world's leading irreversible blinding eye disease. Common types of glaucoma are mainly divided into open-angle glaucoma and closed-angle glaucoma. Studies have shown that glaucoma is a neurodegenerative disease, and its pathological characteristics are the apoptosis of retinal ganglion cells (RGCs) and the degeneration of their axons, as well as the accompanying progressive loss of visual function. RGCs are responsible for outputting visual signals captured by the retina to the brain. Continuous degeneration or apoptosis of RGCs caused by high intraocular pressure, multiple genetic factors, or neurodegenerative diseases can lead to optic nerve head lesions, visual field loss, and then develop into glaucoma. Glaucoma often develops insidiously and progresses slowly. There are generally no obvious symptoms in the early stages, and the visual field gradually shrinks until blindness occurs.

[0003] At present, the clinical diagnosis of glaucoma mainly relies on intraocular pressure, structural examination and functional examination, such as optic disc structure, optic nerve fiber layer and visual field. However, the abnormalities found by such tests are already in the middle and late stages of disease progression, that is, the diagnosis is completed in the "asymptomatic period" or "dysfunctional period" after the optic nerve fiber layer defect, and the progressive damage of RGC in the earlier stage cannot be detected by existing means. In this case, early diagnosis of glaucoma becomes particularly important. Because in the early stages of progressive damage to retinal ganglion cells, existing diagnostic methods often cannot detect changes at the cellular molecular level. If a timely diagnosis can be made at this stage, it will be of great significance to control the occurrence and development of glaucoma.

[0004] The patent document of Chinese patent number CN117147835A found that fecal calprotectin content was significantly related to glaucoma by testing the fecal calprotectin content of glaucoma patients and normal healthy control groups. The detection kit developed based on this principle can detect glaucoma with an AUC of 0.656, a specificity of 0.806, and a sensitivity of 0.451. However, this method has problems such as the sample source cannot directly reflect the condition of the eye tissue, and the detection sensitivity and specificity are not ideal, which may lead to the risk of misdiagnosis or missed diagnosis.

[0005] ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) is an evolutionarily conserved secretory protein and a member of the ALDH family. ALDH1A1 consists of 501 amino acids and its registration number in NCBI is NP_000680.2. ALDH1A1 is a highly conserved homotetrameric cytoplasmic protein with a monomer molecular weight of approximately 55 kDa. Each monomer contains three domains: a catalytic domain, a cofactor (NAD) binding domain, and an oligomerization domain. ALDH1A1 is expressed in many organs or tissues of the human body, such as the brain, testis, liver, kidney, lung, adipose tissue, lens, and retina. Studies have found that changes in the biological activity and metabolic pathways of ALDH1A1 in the body are related to the occurrence and development of a series of diseases, such as cancer, inflammation, Parkinson's disease, obesity, and diabetes.

[0006] However, there are very few studies on the diagnosis of glaucoma by detecting the expression of secretory proteins in the patient's aqueous humor. In addition, there are currently no reports that establish a link between ALDH1A1 and glaucoma diagnosis. Summary of the invention

[0007] In view of this, the present invention creatively proposes to use ALDH1A1 in human aqueous humor as a biomarker for diagnosing glaucoma.

[0008] Since the expression level of ALDH1A1 is significantly increased in the aqueous humor of glaucoma patients, and ALDH1A1 has been shown to promote the apoptosis of retinal ganglion cells (RGCs) in in vitro cell experiments, based on this finding, the inventors infer that ALDH1A1 may be involved in the occurrence of glaucoma and related diseases by promoting the apoptosis of RGCs.

[0009] ALDH1A1 has high universality, sensitivity and specificity in the diagnosis of different types of glaucoma patients. In the diagnosis of open-angle glaucoma, the diagnostic value of ALDH1A1 is 124.20 pg / mL, and its AUC value is 0.9625; in the diagnosis of closed-angle glaucoma, the diagnostic value of ALDH1A1 is 109.53 pg / mL, and its AUC value is 0.9550.

[0010] Therefore, early diagnosis of glaucoma can be achieved by detecting the expression level of ALDH1A1 in aqueous humor. Early detection of glaucoma and taking appropriate treatment measures can effectively prevent the progression of the disease and the occurrence of complications. ALDH1A1 also has great application prospects in monitoring the treatment effect of glaucoma patients, predicting disease progression, and evaluating the prognosis of glaucoma.

[0011] Given that ALDH1A1 promotes apoptosis of retinal ganglion cells in in vitro cell experiments, it may become a potential target for the treatment of glaucoma. By inhibiting or regulating the expression of ALDH1A1, it is expected to reduce apoptosis of retinal ganglion cells, thereby delaying the development of glaucoma and other related diseases.

[0012] The technical solution of the present invention is achieved in this way:

[0013] In a first aspect, the present invention provides a biomarker for diagnosing glaucoma, wherein the biomarker is ALDH1A1.

[0014] In a second aspect, the present invention provides an application of a reagent for detecting ALDH1A1 in preparing a product, wherein the product is used for diagnosing glaucoma. The application comprises: using the product to detect the expression level of ALDH1A1 protein in a sample to be tested, and if the expression level of ALDH1A1 protein is higher than the diagnostic value of 105 pg / mL, glaucoma is diagnosed.

[0015] In a third aspect, the present invention further provides a use of a reagent for detecting ALDH1A1 in preparing a product, wherein the product is used for the prognosis assessment of glaucoma, and the prognosis assessment of glaucoma is performed by using the product to detect changes in the expression level of ALDH1A1 protein in a test aqueous humor sample.

[0016] In a fourth aspect, the present invention further provides the use of ALDH1A1 in the preparation of a drug for treating glaucoma, wherein the drug for treating glaucoma reduces the apoptosis of ganglion cells by inhibiting or regulating the expression of ALDH1A1. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0018] Figure 1 It is the detection result of the protein expression level of the biomarker ALDH1A1 provided by the present invention in the aqueous humor samples of glaucoma patients and the control group (cataract patients), the abscissa represents different aqueous humor samples, and the ordinate represents the ALDH1A1 protein expression level;

[0019] Figure 2 This is the ROC analysis result of ALDH1A1 in the diagnosis of glaucoma;

[0020] Figure 3It is the test result of ALDH1A1 protein expression level in aqueous humor samples of patients with angle-closure glaucoma, patients with open-angle glaucoma and control group (cataract patients). The horizontal axis represents different aqueous humor samples, and the vertical axis represents the ALDH1A1 protein expression level;

[0021] Figure 4 These are the ROC analysis results of ALDH1A1 in the diagnosis of angle-closure glaucoma and open-angle glaucoma;

[0022] Figure 5 and Figure 6 This is the result of PI flow cytometry to detect the effect of ALDH1A1 on ganglion cell apoptosis. Ctrl represents the control group. Figure 5 are the test results of AnnexinV-FITC apoptosis detection kit in the treatment group (ALDH1A1) and control group (Ctrl); Figure 6 is the proportion of apoptotic cells in the treatment group (ALDH1A1) and the control group (Ctrl);

[0023] Figure 7 and Figure 8 It is the result of PI and calcein (PI / Calcein-AM) double staining to detect the effect of ALDH1A1 on ganglion cell apoptosis. Ctrl represents the control group; among them: Figure 7 It is the detection result of PI and calcein (PI / Calcein-AM) double staining in the treatment group (ALDH1A1) and the control group (Ctrl), PI is the red dead cell signal, and Calcein-AM is the green live cell signal; Figure 8 is the ratio of red signals in the treatment group (ALDH1A1) and the control group (Ctrl). DETAILED DESCRIPTION

[0024] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0025] The present invention discovers for the first time that changes in the expression of ALDH1A1 in human aqueous humor are significantly correlated with the occurrence of glaucoma.

[0026] Based on this, in the first aspect of the present invention, ALDH1A1 is proposed as a biomarker for diagnosing glaucoma.

[0027] In a second aspect, the present invention further discloses an application of a reagent for detecting ALDH1A1 in the preparation of a glaucoma diagnostic product, the application comprising: using the product to detect the expression level of ALDH1A1 protein in a sample to be tested, and if the expression level of ALDH1A1 protein is higher than the diagnostic value of 105 pg / mL, glaucoma is diagnosed.

[0028] In some preferred embodiments, the sample to be tested is from aqueous humor.

[0029] Aqueous humor is a colorless, transparent, watery liquid located between the cornea and the lens. It plays an important role in refraction, providing nutrition and oxygen to intraocular tissues, excreting metabolic products, and maintaining intraocular pressure. Because the aqueous humor is in direct contact with intraocular tissues, the detection of eye diseases is more direct and accurate, and can better reflect the condition of eye lesions. As an ocular tissue fluid, the composition of aqueous humor is relatively stable and not easily disturbed by external factors. The blood-retinal barrier is a barrier between the ocular vascular system and the retina, which can effectively limit the entry of substances in the blood into the ocular tissues, thereby making the composition of aqueous humor purer and more stable, reducing external interference, and improving the accuracy of test results. Therefore, compared with blood, collecting aqueous humor as a test sample for glaucoma can better break through the limitations of the blood-retinal barrier and more directly reflect the condition of eye diseases.

[0030] In some preferred embodiments, the components of the product include one or more of antibodies, antibody functional fragments and conjugated antibodies.

[0031] In some preferred embodiments, the product is selected from one or more of an immunoblotting detection kit, an immunochromatography detection kit, a flow cytometry analysis kit, an immunohistochemistry detection kit, an ELISA kit, and an electrochemiluminescence detection kit.

[0032] The antibody functional fragments are variable regions of antibodies, which contain the ability of antibodies to bind to specific antigens. These functional fragments can be used to detect the expression of proteins, for example, by techniques such as immunohistochemistry. The conjugated antibody refers to an antibody conjugated to a specific binding agent, which can specifically recognize and bind to the target protein and can be used for quantitative detection of protein expression levels by detection techniques such as flow cytometry and immunohistochemistry. The specific binding agent has a label for indicating signal intensity, including any one or more of a fluorescent group, a digoxigenin-labeled probe, an electron-dense substance, colloidal gold, and an enzyme.

[0033] In some preferred embodiments, the product is an ELISA kit.

[0034] Furthermore, in some preferred embodiments, the components of the ELISA kit include: a detection antibody labeled with horseradish peroxidase (HRP), a standard substance, a color developing solution, and a stop solution.

[0035] In a third aspect, the present invention further provides a use of a reagent for detecting ALDH1A1 in preparing a product, wherein the product is used for the prognosis assessment of glaucoma, and the prognosis assessment of glaucoma is performed by using the product to detect changes in the expression level of ALDH1A1 protein in a test aqueous humor sample.

[0036] The present invention also discovered for the first time that ALDH1A1 showed a promoting effect on apoptosis of retinal ganglion cells in in vitro cell experiments. Based on this, the inventors proposed that ALDH1A1 may become a potential target for the treatment of glaucoma. By inhibiting or regulating the expression of ALDH1A1, it is expected to reduce apoptosis of retinal ganglion cells, thereby delaying the development of glaucoma and other related diseases.

[0037] Therefore, in a fourth aspect, the present invention further provides the use of ALDH1A1 in the preparation of a drug for treating glaucoma, wherein the drug for treating glaucoma reduces the apoptosis of ganglion cells by inhibiting or regulating the expression of ALDH1A1.

[0038] Furthermore, in some preferred embodiments, the type of glaucoma includes at least one of the following types: (1) closed-angle glaucoma; (2) open-angle glaucoma; (3) glaucoma with pathological characteristics of ganglion cell death.

[0039] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Example 1 Application of the biomarker ALDH1A1 provided by the present invention in the diagnosis of glaucoma

[0040] The present invention collected aqueous humor samples from 30 glaucoma patients and 30 cataract patients, and used an ELISA kit to detect the expression level of ALDH1A1 in the aqueous humor samples. The expression difference of ALDH1A1 in the aqueous humor of glaucoma patients and cataract patients was statistically analyzed. In addition, the present invention also used GraphPad Prism 9.0 to draw a single ROC curve to analyze the specificity, accuracy and sensitivity of ALDH1A1 protein for glaucoma diagnosis. The details are as follows:

[0041] 1.1 Experimental Materials

[0042] The 96-well ELISA plate (8 rows × 12 columns) of ALDH1A1 protein used in the present invention was purchased from Jiangsu Meimian Industrial Co., Ltd., and the ALDH1A1 (human aldehyde dehydrogenase 1 family member A1) ELISA kit used in the present invention was purchased from Jiangsu Meimian Industrial Co., Ltd. (Jiangsu Meimian Industrial Co., Ltd), product number MM-51365H1, and the reagent components are shown in Table 1:

[0043] Table 1

[0044]

[0045] 1.2 Experimental procedures

[0046] (1) Collecting aqueous humor samples

[0047] Aqueous humor was collected from 30 patients with glaucoma, and aqueous humor was collected from 30 patients with cataract (control group). Among them, the aqueous humor of 30 patients with glaucoma came from patients diagnosed by imaging; the aqueous humor of 30 patients with cataract came from cataract patients without any fundus lesions. The collected aqueous humor was placed in a 1.5mL EP tube, and the sample number was marked on the top and side of the EP tube. It was frozen in a -80℃ refrigerator and the collection date and storage location were recorded. Before use, the aqueous humor was taken out and thawed in a 4℃ refrigerator and aliquoted to avoid repeated freezing and thawing.

[0048] (2) ELISA detection of ALDH1A1 protein content

[0049] A) Set up standard wells and sample wells, and add 50 μL of standards of different concentrations to each standard well.

[0050] B) First add 10 μL of the sample to be tested into the sample well, and then add 40 μL of sample diluent.

[0051] C) Add 100 μL of horseradish peroxidase (HRP)-labeled detection antibody to each well and seal the wells with a sealing film. D) Incubate the wells at 37°C in a water bath or incubator for 60 min.

[0052] E) Discard the liquid, pat dry with absorbent paper, fill each well with washing solution, let stand for 1 minute, shake off the washing solution, pat dry with absorbent paper, and repeat this process 5 times.

[0053] F) Add 50 μL of substrate A and B to each well and incubate at 37°C in the dark for 15 min.

[0054] G) Add 50 μL of stop solution to each well and measure the OD value of each well at a wavelength of 450 nm within 15 min.

[0055] (3) t-test analysis

[0056] Draw the standard curve: In the Excel worksheet, use the concentration of the standard as the horizontal axis and the corresponding OD value as the vertical axis to draw the linear regression curve of the standard, and calculate the concentration value of ALDH1A1 in each sample according to the curve equation. The t-test method was used to analyze whether the ALDH1A1 protein levels in the glaucoma group and the control group (cataract group) were significantly different. The test results are as follows Figure 1 shown.

[0057] (4) ROC curve analysis

[0058] GraphPad Prism 9.0 was used to draw ROC curves to analyze the value of ALDH1A1 protein in the diagnosis of glaucoma. Based on the expression levels of ALDH1A1 protein in aqueous humor samples of 30 glaucoma patients and 30 cataract patients, ROC curves were drawn to evaluate the ability of ALDH1A1 to diagnose and distinguish between glaucoma and cataract patients.

[0059] According to the ROC curve of ALDH1A1 protein diagnosis and differentiation of glaucoma and cataract patients, the OD value with the largest Youden index was used as the cutoff value (i.e., the diagnostic value), and the corresponding AUC and 95% confidence interval, sensitivity, and specificity were calculated. Figure 2 shown.

[0060] 1.3 Experimental Results Analysis

[0061] (1) Figure 1 As shown, aqueous humor of glaucoma and cataract patients were collected, and ELISA was used to detect the difference in ALDH1A1 protein levels. The results showed that compared with cataract patients, the ALDH1A1 protein level in the aqueous humor of glaucoma patients was significantly increased, indicating that the expression level of ALDH1A1 is closely linked to glaucoma and can be used as a biomarker for the diagnosis of glaucoma.

[0062] (2) Figure 2 As shown, when ALDH1A1 is used for glaucoma diagnosis, the diagnostic value is 105 pg / mL, and the AUC value of the ROC curve is 0.9588. The results show that the expression level of ALDH1A1 in human aqueous humor has very high specificity, accuracy and sensitivity in the diagnosis of glaucoma.

[0063] Example 2 Application of the biomarker ALDH1A1 provided by the present invention in the diagnosis of angle-closure glaucoma and open-angle glaucoma

[0064] The present invention collected aqueous humor samples from 20 patients with angle-closure glaucoma, 20 patients with open-angle glaucoma and 20 patients with cataract, and used an ELISA kit to detect the expression level of ALDH1A1 protein in each sample. Then, the expression differences of ALDH1A1 in the aqueous humor of patients with angle-closure glaucoma and cataract, and patients with open-angle glaucoma and cataract were statistically analyzed. In addition, the present invention also used GraphPad Prism 9.0 to draw single ROC curves to analyze the specificity, accuracy and sensitivity of ALDH1A1 protein in the diagnosis of angle-closure glaucoma and open-angle glaucoma. The details are as follows:

[0065] 2.1 Experimental Materials

[0066] Same as 1.1 Experimental materials.

[0067] 2.2 Experimental procedures

[0068] (1) Collecting aqueous humor samples

[0069] Aqueous humor was collected from 20 patients with primary angle-closure glaucoma and 20 patients with primary open-angle glaucoma, and aqueous humor was collected from 20 patients with cataract (control group). The collected aqueous humor was placed in a 1.5 mL EP tube, and the sample number was marked on the top and side of the EP tube. It was frozen in a -80°C refrigerator and the collection date and storage location were recorded. Before use, the aqueous humor was taken out and thawed in a 4°C refrigerator and aliquoted to avoid repeated freezing and thawing.

[0070] (2) ELISA detection of ALDH1A1 protein content

[0071] Same as experimental step (2) in 1.2.

[0072] (3) t-test analysis

[0073] Draw the standard curve: In the Excel worksheet, use the concentration of the standard as the horizontal axis and the corresponding OD value as the vertical axis to draw the linear regression curve of the standard, and calculate the concentration value of ALDH1A1 in each sample according to the curve equation. The t-test method was used to analyze whether there was a significant difference in the ALDH1A1 protein levels between the angle-closure glaucoma group, the open-angle glaucoma group and the control group (cataract group). The test results are as follows Figure 3 shown.

[0074] (4) ROC curve analysis

[0075] GraphPad Prism 9.0 was used to draw ROC curves to analyze the diagnostic value of ALDH1A1 protein for angle-closure glaucoma and open-angle glaucoma. Based on the expression level of ALDH1A1 protein in aqueous humor samples of 20 patients with angle-closure glaucoma, 20 patients with open-angle glaucoma, and 20 patients with cataracts, ROC curves were drawn to evaluate the ability of ALDH1A1 to diagnose and distinguish between angle-closure glaucoma and cataracts, and between open-angle glaucoma and cataracts.

[0076] The ROC curves for differentiating angle-closure glaucoma from cataract patients and the ROC curves for differentiating angle-open glaucoma from cataract patients using ALDH1A1 protein were used, respectively. The OD value with the largest Youden index was used as the cutoff value (i.e., the diagnostic value), and the corresponding AUC, 95% confidence interval, sensitivity, and specificity were calculated. The test results are shown in Figure 2. Figure 4 shown.

[0077] 2.3 Experimental Results Analysis

[0078] (1) Figure 3 As shown in the present study, aqueous humor of patients with angle-closure glaucoma, open-angle glaucoma and cataract were collected, and the difference in protein levels of ALDH1A1 was detected by ELISA. The results showed that compared with patients with cataract, the ALDH1A1 protein levels in the aqueous humor of patients with angle-closure glaucoma and open-angle glaucoma were significantly increased, respectively, indicating that the expression level of ALDH1A1 is closely linked to both angle-closure glaucoma and open-angle glaucoma, and can be used as a biomarker for the diagnosis of angle-closure glaucoma and open-angle glaucoma.

[0079] (2) Figure 2 As shown in the figure, when ALDH1A1 is used for the diagnosis of angle-closure glaucoma, the diagnostic value is 124.20 pg / mL, and the AUC value of the ROC curve is 0.9550; when ALDH1A1 is used for the diagnosis of open-angle glaucoma, the diagnostic value is 109.53 pg / mL, and the AUC value of the ROC curve is 0.9625. The results show that the expression level of ALDH1A1 in human aqueous humor has very high specificity, accuracy and sensitivity in the diagnosis of angle-closure glaucoma and open-angle glaucoma.

[0080] Example 3 Studying the Mechanism of Action of ALDH1A1 in Glaucoma and Its Disease

[0081] Glaucoma is an optic neuropathy characterized by progressive retinal ganglion cell apoptosis and decreased visual sensitivity. In view of this, the inventors used ALDH1A1 to treat ganglion cells, and then used PI flow cytometry and PI / Calcein-AM double staining experiments to detect the apoptosis of the treated group (ALDH1A1) and the control group to detect the effect of ALDH1A1 on ganglion cell apoptosis. The details are as follows:

[0082] 3.1 Experimental Materials

[0083] Mouse retinal ganglion cells and mouse retinal ganglion cell culture medium were purchased from Wuhan Punosai Life Science Co., Ltd., catalog number CP-M122; recombinant ALDH1A1 protein was purchased from MCE, USA, catalog number HY-P7474; trypsin-EDTA was purchased from Thermo Fisher Scientific, USA, catalog number 25200114; AnnexinV-FITC apoptosis detection kit was purchased from BioSky Biotechnology, China, catalog number C1062M. PI (catalog number 17517) and Calcein-AM (catalog number 22003) were purchased from AAT Bioquest Biotechnology, USA, dimethyl sulfoxide (catalog number D2650) was purchased from Sigma Biotechnology, USA, and PBS (catalog number BL302A) was purchased from Biosharp Biotechnology, China.

[0084] 3.2 Experimental procedures

[0085] (1) Detection of cell apoptosis level by PI flow cytometry

[0086] A. Ganglion cells were cultured in mouse retinal ganglion cell culture medium and seeded in 6-well plates;

[0087] B. When the cell confluence reached about 60%, the treatment group was stimulated with ALDH1A1 recombinant protein solution (150 pg / mL) for 48 hours, while the control group was not treated with any measures;

[0088] C. Digest the cells with 0.25% trypsin and collect the cell pellet by centrifugation. Add Buffer, PI solution and FITC solution in sequence according to the instructions in the kit and incubate in the dark for 20 minutes.

[0089] D. Flow cytometry was used to detect the percentage of cell apoptosis.

[0090] (2) PI and Calcein (PI / Calcein-AM) double staining to detect cell apoptosis

[0091] i) Mouse retinal ganglion cells were seeded into 24-well plates, and the cell treatment method was the same as step B;

[0092] ii) Prepare PI and Calcein-AM stock solutions: Dissolve 1 mg PI in 1 mL ddH2O to prepare PI stock solution, and dissolve 1 mg Calcein-AM in 1 mL anhydrous dimethyl sulfoxide (DMSO) to prepare Calcein-AM stock solution, and store them in a sealed freezer at -20°C;

[0093] iii) Aspirate the culture medium in the original culture dish, wash twice with preheated sterile phosphate buffered saline (PBS), add 1 mL of culture medium to each dish, then add 2 μL of PI stock solution and 3 μL of Calcein-AM stock solution in sequence, and then place in a 37°C, 5% CO2 incubator for staining for 10 min;

[0094] iv) After 10 minutes, place the sample under an inverted fluorescence microscope for observation. Excite at a wavelength of 490±10 nm to observe the yellow-green living cells. Then excite at a wavelength of 545 nm to observe the red dead cells. Take photos and record.

[0095] 3.3 Experimental Results

[0096] (1) Figure 5 and 6 As shown in the figure, after ALDH1A1 treatment, PI flow cytometry results showed that the apoptotic rate of cells in the treatment group was higher than that in the control group. The results showed that ALDH1A1 has the effect of promoting apoptosis of ganglion cells.

[0097] (2) Figure 7 and 8 As shown in the figure, after ALDH1A1 treatment, the results of PI / Calcein-AM double staining experiments showed that the proportion of red signals in the treated group was higher than that in the control group. The results further demonstrated that ALDH1A1 has the effect of promoting ganglion cell death.

[0098] Given that ALDH1A1 promotes ganglion cell apoptosis, it can be inferred that ALDH1A1 may participate in the occurrence of glaucoma and related diseases by promoting ganglion cell apoptosis. Therefore, ALDH1A1 may become a potential target for the treatment of glaucoma. By inhibiting or regulating the expression of ALDH1A1, it is expected to reduce the apoptosis of retinal ganglion cells, thereby delaying the development of glaucoma and other related diseases.

[0099] In summary, angle-closure glaucoma and open-angle glaucoma can be diagnosed by detecting the expression level of ALDH1A1 in aqueous humor. The expression level of ALDH1A1 may be related to the development and prognosis of glaucoma. Therefore, ALDH1A1 may be used as a biomarker for prognostic evaluation to help doctors evaluate the progression of the disease and predict the effect of treatment.

[0100] Regulation of ALDH1A1 may become a new strategy for the treatment of glaucoma. By inhibiting or regulating the expression of ALDH1A1, it is expected to reduce ganglion cell apoptosis and protect retinal ganglion cells, thereby delaying the progression of glaucoma and alleviating symptoms. Further research on the mechanism of action of ALDH1A1 in the pathogenesis of glaucoma may provide a theoretical basis for the development of new glaucoma treatment drugs and provide more effective treatment options for glaucoma patients.

[0101] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Use of a reagent for detecting ALDH1A1 in preparing a product, characterized in that: The product is used to diagnose and differentiate glaucoma from cataracts, and the application includes: using the product to detect the expression level of ALDH1A1 protein in a sample to be tested, and if the expression level of ALDH1A1 protein is higher than the diagnostic value of 105 pg / mL, glaucoma is diagnosed.

2. The use according to claim 1, characterized in that The sample to be tested comes from aqueous humor.

3. The use according to claim 1, characterized in that: The components of the product include one or more of antibodies, antibody functional fragments and conjugated antibodies.

4. The use according to claim 1, characterized in that The product is selected from one or more of an immunoblotting detection kit, an immunochromatography detection kit, a flow cytometry analysis kit, an immunohistochemistry detection kit, an ELISA kit and an electrochemiluminescence detection kit.

5. The use according to claim 1, characterized in that The product is an ELISA kit.

6. The use according to claim 5, characterized in that The components of the ELISA kit include: detection antibody labeled with horseradish peroxidase, standard substance, color developing solution and stop solution.

7. The use according to any one of claims 1 to 6, characterized in that The type of glaucoma includes at least one of the following types: (1) closed-angle glaucoma; (2) open-angle glaucoma.